Implitapide in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) on Maximal Concurrent Lipid-Lowering Therapy
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The purpose of this study is to determine if implitapide, used in conjunction with other lipid-lowering therapies, is safe and effective when compared to placebo in lowering low-density lipoprotein cholesterol (LDL-C) in patients with heterozygous familial hypercholesterolemia (HeFH).
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 70 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
In order to participate in this study, patients must meet all of the following inclusion criteria:
be between 18 and 70 years old with a diagnosis of HeFH;
be stable on and maintain concomitant therapy with hypolipidemic drugs or treatments;
have an appropriate calculated, fasting LDL-C levels and an appropriate triglyceride (TG) level;
be male or nonpregnant, nonlactating female;
give informed consent; and
meet body weight requirements.
In order to participate in this study, patients must not meet any of the following exclusion criteria: